Dag Nesse
Directeur Technique/Scientifique/R&D chez ABLIVA AB
Profil
Dag Nesse is currently the Vice President-Clinical Operations at Abliva AB since 2023.
Prior to this, he worked as the Director-Clinical Operations at EpiEndo Pharmaceuticals ehf and as the Head-Clinical Operations at Modus Therapeutics AB.
Mr. Nesse completed his undergraduate degree from the University of Oslo and BI Norwegian Business School.
Postes actifs de Dag Nesse
| Sociétés | Poste | Début |
|---|---|---|
| ABLIVA AB | Directeur Technique/Scientifique/R&D | 01/02/2023 |
Anciens postes connus de Dag Nesse
| Sociétés | Poste | Fin |
|---|---|---|
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Directeur Technique/Scientifique/R&D | - |
EpiEndo Pharmaceuticals ehf
 EpiEndo Pharmaceuticals ehf BiotechnologyHealth Technology EpiEndo Pharmaceuticals ehf is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland. The Icelander company focuses on enhancing epithelial barrier integrity to treat inflammatory disorders, with a primary focus on chronic respiratory diseases. The company recently appointed Dr. Kate Hanrott as Director of Clinical Operations and Sciences, bringing extensive experience to the role. EpiEndo Pharmaceuticals will be attending the Bio International Convention in June 2023. EpiEndo Pharmaceuticals was founded in 2014 by Fridrik Gardarsson, and Maria Bech has been the CEO of the company since 2021. | Directeur Technique/Scientifique/R&D | - |
Formation de Dag Nesse
| University of Oslo | Undergraduate Degree |
| BI Norwegian Business School | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ABLIVA AB | Health Technology |
| Entreprise privées | 2 |
|---|---|
EpiEndo Pharmaceuticals ehf
EpiEndo Pharmaceuticals ehf BiotechnologyHealth Technology EpiEndo Pharmaceuticals ehf is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland. The Icelander company focuses on enhancing epithelial barrier integrity to treat inflammatory disorders, with a primary focus on chronic respiratory diseases. The company recently appointed Dr. Kate Hanrott as Director of Clinical Operations and Sciences, bringing extensive experience to the role. EpiEndo Pharmaceuticals will be attending the Bio International Convention in June 2023. EpiEndo Pharmaceuticals was founded in 2014 by Fridrik Gardarsson, and Maria Bech has been the CEO of the company since 2021. | Health Technology |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
